In Vitro and In Vivo Evaluation of a Small-Molecule APJ (Apelin Receptor) Agonist, BMS-986224, as a Potential Treatment for Heart Failure.

Publication — IRIC

New heart failure therapies that safely augment cardiac contractility and output are needed. Previous apelin peptide studies have highlighted the potential for APJ (apelin receptor) agonism to enhance cardiac function in heart failure. However, apelin’s short half-life limits its therapeutic utility. Here, we describe the preclinical characterization of a novel, orally bioavailable APJ agonist, BMS-986224.

Date de publication: 1^st March 2021
Chercheur(euse)s: Gargalovic P, Wong P, Onorato J, Finlay H, Wang T, Yan M, Crain E, St-Onge S, Héroux M, Bouvier M, Xu C, Chen XQ, Generaux C, Lawrence M, Wexler R, Gordon D
Référence PubMed: Circ Heart Fail 2021;14(3):e007351
ID PubMed: 33663236
Affiliation: Bristol Myers Squibb, Drug Discovery, Princeton, NJ (P.G., P.W., J.O., H.F., T.W., M.Y., E.C., C.X., X.-Q.C., C.G., M.L., R.W., D.G.).